Protein kinases: From targets to anti-cancer drugs;Protéines kinases: des cibles aux médicaments anti-cancéreux

Annales Pharmaceutiques Francaises

Volumn 68, Issue 4, 2010, Pages 254-259

  Cruzalegui, F ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Inhibitor; Kinases; Profile

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; IMATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; PROTEIN BINDING; TUMOR PROTEIN;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; PROTEIN STRUCTURE; REVIEW; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYMOLOGY; NEOPLASMS; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUBSTRATE SPECIFICITY;

EID: 77954762507     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.03.007     Document Type: Review

References (15)

1. Fischer E.H., Krebs E.G. Conversion of phosphorylase b to phosphorylase a in muscle extracts. J Biol Chem 1955, 216:121-132.
2. Boulton T.G., Gregory J.S., Cobb M.H. Purification and properties of extracellular signal-regulated kinase 1, an insulin-stimulated microtubule-associated protein 2 kinase. Biochemistry 1991, 30:278-286.
3. Rossomando A.J., Payne D.M., Weber M.J., Sturgill T.W. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc Natl Acad Sci USA 1989, 86:6940-6943.
4. Hunter T., Sefton B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 1980, 77:1311-1315.
5. Parker R.C., Varmus H.E., Bishop J.M. Cellular homologue (c-src) of the transforming gene of Rous sarcoma virus: isolation, mapping and transcriptional analysis of c-src and flanking regions. Proc Natl Acad Sci USA 1981, 78:5842-5846.
6. Gonzalez G.A., Montminy M.R. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989, 59:675-680.
7. Marais R., Wynne J., Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993, 73:381-393.
8. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
9. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991, 253:407-414.
10. Xu W., Doshi A., Lei M., Eck M.J., Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999, 3:629-638.
11. Johnson L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev Biophys 2009, 42:1-40.
12. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
13. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001, 21:499-512.
14. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
15. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046.